ESMO 2019: PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that…
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that…